EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, UnicoCell Biomed Co's Enterprise Value is NT$4,731.87 Mil.
UnicoCell Biomed Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-97.04 Mil. Therefore, UnicoCell Biomed Co's EV-to-FCF for today is -48.76.
The historical rank and industry rank for UnicoCell Biomed Co's EV-to-FCF or its related term are showing as below:
TPE:6794'
s EV-to-FCF Range Over the Past 10 Years
Min: -156.52 Med: -53.03 Max: -37.08
Current: -47.06
During the past 9 years, the highest EV-to-FCF of UnicoCell Biomed Co was -37.08. The lowest was -156.52. And the median was -53.03.
TPE:6794's EV-to-FCF is ranked worse than 100% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs TPE:6794: -47.06
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
UnicoCell Biomed Co (TPE:6794) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
UnicoCell Biomed Co's PE Ratio (TTM) for today is calculated as:
UnicoCell Biomed Co's share price for today is NT$85.20.
UnicoCell Biomed Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.890.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
UnicoCell Biomed Co EV-to-FCF Related Terms
UnicoCell Biomed Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6794 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, UnicoCell Biomed Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's EV-to-FCF falls into.
UnicoCell Biomed Co's current Enterprise Value is NT$4,731.87 Mil.
UnicoCell Biomed Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-97.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UnicoCell Biomed Co (TPE:6794) has a EV-to-FCF of -48.76 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on UnicoCell Biomed Co and its competitors. According to the industry distribution chart, UnicoCell Biomed Co ranks #999999 out of 327 companies in the Biotechnology industry.
Is UnicoCell Biomed Co's EV-to-FCF too high?
UnicoCell Biomed Co's current EV-to-FCF is -48.76. Based on the distribution chart, UnicoCell Biomed Co ranks #999999 out of 327 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, UnicoCell Biomed Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #999999 out of 327 companies for EV-to-FCF. This places UnicoCell Biomed Co in the lower half of its industry. The industry median EV-to-FCF is 16.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on UnicoCell Biomed Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UnicoCell Biomed Co's current EV-to-FCF is -48.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$101.57, compared to a current price of NT$85.20 — trading 16.1% below its estimated fair value. The current EV-to-FCF is -48.76. UnicoCell Biomed Co's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current EV-to-FCF is -48.76 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued.
The current stock price of NT$85.20 is trading 16.1% below its estimated GF Value™ of NT$101.57.
GuruFocus considers UnicoCell Biomed Co to be Modestly Undervalued.
Key valuation signals for TPE:6794:
EV-to-FCF: -48.76
GF Value™: NT$101.57 vs. price of NT$85.20 (16.1% below fair value)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
83GF Score
Get the complete analysis for TPE:6794
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
